Table 1.
Baseline characteristics of study eyes.
| Overall | Bevacizumab | Ranibizumab | p | |
|---|---|---|---|---|
| Eyes, n | 203 | 85 | 118 | |
| Patients, n | 189 | 81 | 114 | |
| Female, n (%) | 135 (71) | 59 (73) | 80 (70) | 0.49 |
| Age years, mean (SD) | 63.5 (15.5) | 61 (16) | 65 (15) | 0.08 |
| Refractive error diopters, mean (SD)a | −13 (5) | −13 (5) | −13 (5) | 0.65 |
| Ethnicity | ||||
| Caucasian, n (%) | 184 (97) | 78 (96) | 112 (98) | 0.47 |
| Asian, n (%) | 1 (1) | 1 (1) | 0 (0) | |
| Other ethnicity, n (%) | 4 (2) | 2 (3) | 2 (2) | |
| Lens status (phakic), n (%) | 108 (53) | 50 (59) | 58 (49) | 0.22 |
| VA letters, mean (SD) | 52 (20) | 51 (18) | 54 (22) | 0.30 |
| VA ≥70 letters, % | 25 | 19 | 29 | |
| VA ≤35 letters, % | 22 | 22 | 21 | |
| Multimodal imaging grading* | ||||
| Presence of subretinal fibrosis, n (%) | 75 (37) | 40 (47) | 35 (30) | 0.019 |
| Subfoveal subretinal fibrosis, n (%) | 43 (57) | 20 (50) | 23 (66) | |
| Presence of macular atrophy, n (%) | 105 (52) | 51 (60) | 54 (47) | 0.09 |
| Subfoveal macular atrophy, n (%) | 32 (31) | 13 (26) | 19 (35) | |
| Angiographic lesion size μm, median (Q1, Q3)* | 870 (580, 1300) | 880 (633, 1200) | 840 (580, 1500) | 0.64 |
Significant p‐values are highlighted in bold.
n = number; SD = standard deviation; VA = visual acuity.
*
Missing data for refractive error (n = 62), multimodal imaging grading (n = 2 eyes) and angiographic lesion size (n = 120).